Phlexglobal has announced the general availability of PhlexTMF v21: an eTMF solution with artificial intelligence. Organizations can utilize PhlexTMF v21 to reduce TMF document misfiles and metadata errors—improving TMF quality, completeness, and timeliness.
PhlexTMF v21 immediately enables new as well as experienced document submitters to:
Phlexglobal Announces Industry-First eTMF AI that Reduces Risk of Document Misfiles and Metadata Errors to Improve TMF Quality and Inspection-Readiness. (2023, March 20). Phlexglobal.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.